Literature DB >> 15337531

Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells.

Julius Halaschek-Wiener1, Volker Wacheck, Yoel Kloog, Burkhard Jansen.   

Abstract

Activated Ras, operating through the Raf/MEK/ERK pathway, is known to regulate transcription of both Mdm2 and its inhibitor p19ARF, resulting in opposing effects on the tumor suppressor protein p53. We show here that a decrease in Ras in SW480 cells induced either by the Ras inhibitor farnesylthiosalicylic acid (FTS) or by K-Ras antisense oligonucleotides, resulted in a similar increase in p53 protein. The increase in p53 was accompanied by an increase in p21(waf1/cip1) mRNA transcripts and protein. Consistent with the Ras/Raf/MEK/ERK-mediated control of Mdm2, treatment of SW480 cells with the Ras inhibitor FTS caused a marked (80%) decrease in Mdm2, which itself would account for the increase in p53. However, FTS also caused a 1.6-fold increase in p53 mRNA, indicative of a Ras-dependent mechanism that regulates p53 transcription. Thus, oncogenic Ras appears to attenuate p53 in SW480 cells by two independent regulatory mechanisms, the one leading to increased Mdm2-dependent p53 degradation and the other leading to a decrease in p53 transcription.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337531     DOI: 10.1016/j.cellsig.2004.04.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  14 in total

1.  Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells.

Authors:  Sung-Po Hsu; Wen-Sen Lee
Journal:  Mol Endocrinol       Date:  2011-01-14

Review 2.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 3.  Mdm2 links genotoxic stress and metabolism to p53.

Authors:  Zhongfeng Wang; Baojie Li
Journal:  Protein Cell       Date:  2011-01-08       Impact factor: 14.870

4.  Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function.

Authors:  Sun-Hye Lee; Su-Jin Lee; Yeon Sang Jung; Yongbin Xu; Ho Sung Kang; Nam-Chul Ha; Bum-Joon Park
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

Review 5.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

6.  Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Authors:  Nicolas Charette; Christine De Saeger; Valérie Lannoy; Yves Horsmans; Isabelle Leclercq; Peter Stärkel
Journal:  Mol Cancer       Date:  2010-09-22       Impact factor: 27.401

7.  The molecular pathogenesis and clinical implications of hepatocellular carcinoma.

Authors:  Makoto Meguro; Toru Mizuguchi; Masaki Kawamoto; Koichi Hirata
Journal:  Int J Hepatol       Date:  2011-12-04

Review 8.  Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

Authors:  Guilherme A P de Oliveira; Luciana P Rangel; Danielly C Costa; Jerson L Silva
Journal:  Front Oncol       Date:  2015-04-29       Impact factor: 6.244

9.  Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis.

Authors:  Batya Barkan; Adrienne D Cox; Yoel Kloog
Journal:  Oncotarget       Date:  2013-02

10.  Ras inhibition enhances autophagy, which partially protects cells from death.

Authors:  Eran Schmukler; Efrat Grinboim; Sari Schokoroy; Adva Amir; Eya Wolfson; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  Oncotarget       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.